Jul 2, 2026 06:46AM
Jun 29, 2026 06:30AM
Jun 29, 2026 06:30AM
Jun 26, 2026 04:05PM
Jun 26, 2026 04:05PM
May 27, 2026 01:09AM
May 15, 2026 05:03AM Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens
May 14, 2026 07:00AM
Apr 30, 2026 04:05PM
Mar 19, 2026 02:38PM
Mar 19, 2026 12:57PM
Mar 19, 2026 07:00AM
Mar 3, 2026 09:30AM
Feb 24, 2026 10:17AM Biotech and Big Tech Drive the Morning Narrative
Feb 24, 2026 07:00AM
Feb 24, 2026 07:00AM
Jan 5, 2026 06:20AM
Nov 5, 2025 07:00AM
Sep 30, 2025 04:05AM
Sep 29, 2025 07:02AM
Sep 29, 2025 07:00AM Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
Sep 28, 2025 05:00PM
Sep 16, 2025 06:51AM
Aug 19, 2025 04:12AM
Aug 14, 2025 02:19PM
Aug 14, 2025 07:00AM
Jul 8, 2025 07:02AM
Jul 8, 2025 07:00AM Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
Jun 25, 2025 06:07AM
Jun 23, 2025 01:29PM
Jun 23, 2025 08:27AM
Jun 23, 2025 07:01AM
Jun 23, 2025 07:00AM
Jun 20, 2025 04:05PM
Apr 30, 2025 07:00AM Larimar Therapeutics Reports First Quarter 2025 Financial Results
Apr 23, 2025 04:21AM
Mar 25, 2025 12:52PM
Mar 25, 2025 06:49AM
Mar 25, 2025 04:24AM
Mar 24, 2025 07:01AM
Mar 24, 2025 07:00AM
Jan 24, 2025 05:18AM JMP Securities Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)
Jan 23, 2025 04:05PM
Dec 17, 2024 06:53AM
Dec 16, 2024 02:38PM
Dec 16, 2024 02:23PM
Dec 16, 2024 01:55PM
Dec 16, 2024 07:02AM
Dec 16, 2024 07:00AM Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia
Nov 19, 2024 06:56AM

325,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All